MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia

    W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, M. Sanchez, W. Shanahan (New York, NY, USA)

    Objective: To understand the effects of nelotanserin on objective sleep parameters in a phase 2 study in patients with primary insomnia. Background: Nelotanserin is a…
  • 2016 International Congress

    Priapism and hypersexuality associated with rotigotine in an elderly Parkinsonian patient: A case report

    A. Cannas, M. Meloni, M.M. Mascia, P. Solla, G. Orofino, R. Farris, D. Ciaccio, E. Binaghi, F. Marrosu (Nuoro, Italy)

    Objective: To describe reversible rotigotine - induced priapism and hypersexuality in a 79-year-old left-handed male with Parkinson's disease (PD). Background: Priapism is a urological emergency…
  • 2016 International Congress

    The unfolded protein response pathway as a possible therapeutic target for the synucleinopathies

    J.H. Baek, E. Bereczki, D. Aarsland (Stockholm, Sweden)

    Objective: To investigate whether the pharmacological inhibition of unfolded protein response (UPR) pathway would be beneficial in cellular model of synucleinopathies. Background: It has been…
  • 2016 International Congress

    Novel training based on declarative memory cues improves gait perfromance in patients with Parkinson’s disease: A randomized clinical trial

    M.E.P. Piemonte, E. Okamoto, K.R. Cardoso, T.P. Oliveira, C.S. Miranda, M. Pikel, F. Mendes, G.F. Xavier (Sao Paulo, Brazil)

    Objective: To verify the long-term efficiency of a new strategy based on declarative memory cues to improve the gait performance and independence in activities of…
  • 2016 International Congress

    Virtual rehabilitation: A therapy for parkinsonism?

    B.S. Zeigelboim, G.J.B. Santos, M.I.R. Severiano, H.A.G. Teive, A.B.M. Lacerda, C.M. Porto (Curitiba, Brazil)

    Objective: To determine the effectiveness of vestibular rehabilitation exercises that use virtual reality technology through pre and post application of the Berg Balance Scale (BBS),…
  • 2016 International Congress

    Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease

    J.B. Rowe, C. Rae, C. Nombela, T. Ham, P. Vazquez, I. Coyle-Gilchrist, C.R. Housden, B.J. Sahakian, T.W. Robbins, Z. Yes (Cambridge, United Kingdom)

    Objective: (1) To reassess the behavioral impact of novel noradrenergic (atomoxetine) and serotonergic (citalopram) therapies for impulsivity and (2) to develop predictive models to identify…
  • 2016 International Congress

    Factors associated with falling in early, treated Parkinson’s disease: The NET-PD LS1 cohort

    K.L. Chou, J.J. Elm, C.L. Wielinski, D.K. Simon, M.J. Aminoff, C.W. Chadwick, G.S. Liang, R.A. Hauser, L. Sudarsky, C.C. Umeh, T. Voss, J. Juncos, J.Y. Fang, J.T. Boyd, I. Bodis-Wollner, M. Zoltan, J.C. Morgan, A.M. Wills, S.L. Lee, S.A. Parashos, On behalf of the NINDS NET-PD Investigators (Ann Arbor, MI, USA)

    Objective: To examine baseline characteristics associated with falling in PD using the NET-PD LS-1 dataset. Background: Recognizing the factors associated with falling in Parkinson's disease…
  • 2016 International Congress

    Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

    K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

    Objective: The aim of this randomized controlled study was to assess the effect of the electronic medication dispenser, Medido, on physical limitations in PD. Background:…
  • 2016 International Congress

    Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up

    B.J. Snow, E. Mulroy, M. Simpson, L. Macdonald, A. Bok, K. Taylor, J. Han, K. Durbin (Auckland, New Zealand)

    Objective: To follow the clinical status of 4 PD patients transplanted with NTCELL out to 81-130 weeks. Background: NTCELL comprises neonatal porcine choroid plexus cells…
  • 2016 International Congress

    Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

    S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

    Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley